Calcineurin–Signal transducer and activator of transcription 3 (STAT3) signaling axis (Cn-STAT3)

The Calcineurin–Signal transducer and activator of transcription 3 (STAT3) signaling axis is a regulatory pathway where the calcium-dependent phosphatase Calcineurin modulates the activity and stability of the transcription factor STAT3. Calcineurin can regulate STAT3 through direct dephosphorylation, particularly at the Tyr705 residue, or by promoting its proteasomal degradation via the ubiquitin-proteasome pathway (PubMed, 2012). Additionally, Calcineurin can indirectly activate STAT3 signaling through the induction of inflammatory cytokines such as IL-6 via the NFAT transcription factor family (Nature Medicine, 2016). In normal physiological contexts, this axis is involved in neurotrophin dependence during brain development and the regulation of immune responses (PMC, 2012). However, in various malignancies such as colorectal cancer, glioblastoma, and leukemia, the axis is aberrantly activated, often as a result of microbiota-induced toll-like receptor (TLR) signaling or chronic inflammation (AACR, 2022). This activation supports the maintenance and proliferation of cancer stem cells (CSCs) and facilitates immune evasion by upregulating coinhibitory molecules like B7-H3 and B7-H4 (PubMed, 2022). Therapeutic strategies targeting this axis include the use of Calcineurin inhibitors, such as Cyclosporine A and Tacrolimus, as well as STAT3-specific inhibitors like Napabucasin, to disrupt oncogenic signaling and enhance anti-tumor immunity (PubMed, 2014). Despite its therapeutic potential, targeting this axis presents challenges, including the risk of systemic immunosuppression and nephrotoxicity associated with long-term Calcineurin inhibition (StatPearls, 2023).

Other names

Calcineurin-STAT3 signaling axisCalcineurin-STAT3 pathwayCn-STAT3 axisCalcineurin-mediated STAT3 regulationCalcineurin-STAT3 interaction

Calcineurin dephosphorylates STAT3 or promotes its proteasomal degradation; inhibitors of Calcineurin stabilize STAT3 or prevent its dephosphorylation, while STAT3 inhibitors block its transcriptional activity.